Begin januari vertrok Steven Holtzman als commissaris bij AMT, omdat hij een functie aanvaard heeft bij Biogen. Ik vond dat toen al een raar bericht, omdat al die commissarissen in de Pharma barsten van de (neven)functies. Dus is het aanvaarden van een functie normaal gesproken geen reden om te stoppen als commissaris.
Tenzij er belangenverstrengeling dreigt. En dat zou wel eens het geval kunnen zijn als Biogen de onderneming is die nu snuffelt in de boeken.
Hieronder een stukje van hun site, dat doet vermoeden dat Biogen en AMT wel eens heel goed bij elkaar kunnen passen:
At Biogen Idec, we believe strongly in the value of successful partnerships, and we do everything we can to make them work. If your company is in the later stages of development, Biogen Idec can provide a wealth of resources to help successfully commercialize your product.
Our approach to partnerships is driven by two core principles that promote success: respect and flexibility.
Biogen Idec has a history of successful collaborations, licensing arrangements and acquisitions because we are driven not by ideology but by pragmatism. Our goals are the same as our partners'; to successfully bring effective treatments to the market. We are willing to make whatever kind of arrangement is needed to make that happen.
Among our acquisitions, we are flexible as to whether our partner continues as a wholly-owned independent subsidiary, or becomes part of the parent company. (We have successfully completed both.)
Many of our partners are attracted to us by our size. We are big enough to provide crucial capabilities that our partners lack, including clinical development, FDA approval, manufacturing, marketing and all other aspects of commercializing a product. At the same time, we have internal structures in place to assure the ongoing commitment of senior management, so that our partners get what they need to be successful.
Furthermore, we don't lump all our partnerships together. We manage each partnership based on its needs. The people working with you are experienced and knowledgeable in your therapeutic area and stage of product development.
We are interested in partnerships in our core therapeutic area of neurology and other areas of high unmet need. In addition, we welcome products in acute care, including cardiovascular, hemophilia, infectious disease, and other products used in a hospital environment. We also have active programs in hemophilia research and development. In fact, we are open to partnerships in additional therapeutic areas that lend themselves to a specialty biopharma business model.